Search clinical trials for: Pegylated-Interferon and Ribavirin

Total 2637 results

The University of Hong Kong
Hospital Authority, Hong Kong

Completed

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Novel Coronavirus Infection

Hong Kong
Sawa Ito, MD
Horizon Pharma USA, Inc.

Completed

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Myelodysplastic Syndromes | Myeloid Leukemia | Allogeneic Stem Cell Transplantation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes

Hepatitis C

United States
Interferon Sciences

Completed

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

HIV Infections

United States
Purdue Frederick
Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation...

Completed

Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection

HIV Infections

United States
Casa Sollievo della Sofferenza IRCCS
University of Palermo; University of Florence; Campus Bio-Medico University; IRCCS... and other collaborators

Completed

Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) (WRITE)

Chronic Hepatitis

Italy
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Cinnagen

Completed

Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)

Healthy | Bioequivalence

Finland
Bayer

Completed

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Germany, Austria, United Kingdom, Israel, Belgium, Finland
Peking University People's Hospital

Unknown

Interferon-α After DLI for the Prevention of Relapse (IDPR-HSCT)

Leukemia

China
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Withdrawn

Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)

Liver Cirrhosis | HIV Infections | Hepatitis C
Bayer

Completed

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Multiple Sclerosis

Belgium, Italy, Spain, France, Germany, Canada, Switzerland, Austria, Denmark, Hungary, Netherlands, Poland, Israel, United Kingdom, Finland, Sweden, Norway, Czech Republic, Portugal, Slovenia
EMD Serono
Pfizer

Completed

RNF and Betaseron® Tolerability Study (REFORMS)

Relapsing Remitting Multiple Sclerosis (RRMS)

United States
Pusan National University Yangsan Hospital
Pusan National University Hospital; Inje University; Severance Hospital; Soon Chun... and other collaborators

Unknown

PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

Chronic Hepatitis C

Korea, Republic of
University Hospital, Limoges
Hoffmann-La Roche

Completed

Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM (CINAM)

Chronic Hepatitis C

France
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3

Hepatitis C, Chronic

Austria
Foundation for Liver Research
Hoffmann-La Roche

Terminated

High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4 (VIRID)

Chronic Hepatitis C

Netherlands
EMD Serono
Merck Serono International SA

Completed

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Ulcerative Colitis

Sweden, Germany, Netherlands, Israel, Singapore, Switzerland, United Kingdom
Sun Yat-sen University
First People's Hospital of Foshan; Eighth Affiliated Hospital, Sun Yat-sen...

Recruiting

To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. (IFNA2/ISGs)

Hepatitis B

China
Bayer

Completed

Depression and Fatigue in MS Patients Treated With Betaferon. (FADO)

Multiple Sclerosis

Poland
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Multiple Sclerosis

Germany
Bayer

Completed

BENEFIT Extension Study

Multiple Sclerosis

Switzerland, Poland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Slovenia, Israel, Belgium, Denmark, Netherlands, Canada, Norway, Finland
Synairgen Research Ltd.

Completed

A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Bayer

Completed

China Betaferon Adherence, Coping and Nurse Support Study

Multiple Sclerosis, Chronic Progressive

China
Bayer

Completed

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (SEPLUS)

Multiple Sclerosis

France
Rutgers, The State University of New Jersey
Bayer

Completed

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (REMAIN)

Multiple Sclerosis, Relapsing-Remitting
Bayer

Completed

Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis (BREAK)

Multiple Sclerosis

Poland
Bayer

Completed

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

Multiple Sclerosis

Switzerland, France, Germany, Indonesia, Korea, Republic of, Spain, Sweden, Thailand, Taiwan, Australia, Austria, Colombia, Czech Republic, Italy, Jordan, Kazakhstan, Lebanon, Mexico, Slovenia, United Kingdom, Bahrain, Egypt, United... and more
Bayer

Completed

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Multiple Sclerosis

Canada, United States
Hoffmann-La Roche

Completed

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Pediatric Immuno-Tolerant Chronic Hepatitis B

United States, Belgium, Australia, Germany, Italy, Malaysia, Romania, Russian Federation, Taiwan, Turkey, Ukraine, United Kingdom
University Hospital, Bonn
Hoffmann-La Roche

Terminated

Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

HIV Infections | Chronic Hepatitis B

Germany
Beijing Ditan Hospital

Unknown

A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis

Chronic Hepatitis b

China
Tongji Hospital

Unknown

Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients

COVID-19 | Recombinant Human Interferon α1β
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Relapsing Remitting Multiple Sclerosis
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Bayer

Completed

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (INFLUENCE)

Multiple Sclerosis

Poland
Bayer

Completed

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Multiple Sclerosis

China
Bayer

Withdrawn

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis

Sweden, Denmark
Bayer

Completed

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Unspecified Childhood Solid Tumor, Protocol Specific | Neoplasm of Uncertain Malignant Potential

United States
Bayer

Completed

Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy

Heart Diseases | Cardiomyopathies

Italy, Spain, Germany, Poland, United Kingdom, Sweden, France
Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
University of Chicago

Unknown

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Immune System Diseases | Multiple Sclerosis

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Melanoma (Skin)

United States
Novartis Pharmaceuticals

Completed

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) (NICOLI)

Chronic Myeloid Leukemia

Germany
University of Arizona

Completed

Cognitive Effects of Interferon in Patients With Melanoma

Melanoma

United States
European Organisation for Research and Treatment...

Unknown

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Switzerland, Netherlands, Poland, Finland, Belgium, United Kingdom, Austria, Germany, Italy, Israel, Slovakia, Spain, Serbia, Portugal, Russian Federation, Bulgaria, Croatia, Turkey, Estonia, Sweden

3

Subscribe